CagriSema vs Tirzepatide — REDEFINE 4 Head-to-Head Results→
Novo Nordisk’s CagriSema directly versus Eli Lilly’s tirzepatide in the REDEFINE 4 superiority trial. Weight loss, GI tolerability, and discontinuation rates compared.
Research Library
Research Library
Clinical data comparisons, mechanism of action guides, approval trackers, and compound profiles for retatrutide, tirzepatide, CagriSema, survodutide, and the obesity drug pipeline.
37 articles across 6 research clusters
COA-VERIFIED RESEARCH PEN
Retatrutide Pen 30mg — Ready to Order
99.262% HPLC purity, Janoshik-verified. Prefilled FlexiPen, 2-hour UAE delivery. From AED 1,000/pen.
Retatrutide vs Tirzepatide vs CagriSema — 2026 Clinical Data Comparison
Triple agonist vs dual agonist vs amylin+GLP-1 combination — receptor targets, mean weight reduction data, half-life, clinical trial status, and mechanism compared in a single data table.
Cluster 01
Head-to-Head Comparisons
Side-by-side clinical data for every major obesity compound matchup. Weight loss outcomes, receptor profiles, trial stages, and practical differences.
Comparison
Comparison
Survodutide vs Retatrutide — Dual Agonist vs Triple Agonist→
Two-receptor vs three-receptor approach — survodutide (GLP-1/glucagon) versus retatrutide (GLP-1/GIP/glucagon). Phase 2 data, receptor profiles, and clinical paths compared.
Comparison
Retatrutide vs Orforglipron — Triple Agonist vs Oral GLP-1→
Injectable triple agonist versus oral small-molecule GLP-1. Different mechanisms, different delivery, different clinical data. Head-to-head positioning for the pipeline.
Disambiguation
Zenagamtide vs CagriSema — Single Molecule vs Fixed-Dose Combination→
Both target GLP-1 and amylin pathways. Both are Novo Nordisk. But zenagamtide is one molecule; CagriSema is two drugs combined. Molecular architecture and strategy compared.
Disambiguation
Petrelintide vs CagriSema — Amylin Monotherapy vs GLP-1/Amylin Combo→
Petrelintide is a standalone amylin analog by Roche/Zealand. CagriSema combines cagrilintide + semaglutide. Different architecture, different developers, different strategy.
Safety Comparison
Ozempic vs Mounjaro vs Wegovy — Side Effects Compared→
Side-by-side GI side effects, injection site reactions, and rare adverse events from clinical trial data. Frequency percentages for nausea, vomiting, diarrhea, and more.
Ranking
What Is the Best Obesity Drug in 2026? A Data-Driven Comparison→
Ranking approved and investigational obesity drugs by weight loss efficacy, mechanism breadth, tolerability data, and regulatory status. Data from published clinical trials only.
Cluster 02
Mechanisms & Compound Profiles
How each compound works at the receptor level. Molecular architecture, agonist targets, pharmacokinetics, and clinical development status.
Mechanism of Action
The Triple Agonist Pathway — GIP, GLP-1 & Glucagon→
How the three metabolic receptors interact in retatrutide. Individual receptor functions, synergistic effects, the glucagon paradox, and receptor expression map.
Compound Profile
CagriSema — Amylin + GLP-1 Combination→
Fixed-ratio combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) by Novo Nordisk. Non-overlapping satiety pathways — distinct from incretin-based agonists.
Compound Profile
Survodutide — Dual GLP-1/Glucagon Agonist for Obesity & MASH→
Boehringer Ingelheim and Zealand Pharma’s dual agonist. Phase 2 data: up to 18.7% weight loss at 46 weeks. Phase 3 MASH programme with FDA Breakthrough Therapy designation.
Compound Profile
Zenagamtide (Amycretin) — GLP-1/Amylin Dual Agonist→
Novo Nordisk’s unimolecular GLP-1/amylin dual agonist. Phase 2 data: up to 14.5% weight loss at 36 weeks. Phase 3 obesity trials planned Q1 2026.
Compound Profile
Petrelintide — Roche & Zealand’s Amylin-Based Obesity Approach→
Once-weekly long-acting amylin analog (not a GLP-1 drug). Phase 2 ZUPREME-1 data: up to 10.7% mean weight loss at 42 weeks. No GI discontinuations at the maximally effective dose.
Compound Profile
Mazdutide (IBI362) — Dual GLP-1R/GCGR Agonist→
Dual agonist targeting GLP-1 and glucagon receptors, developed by Innovent Biologics. Approved in China (2025). Omits GIP — isolates GLP-1+GCGR synergy for comparison with retatrutide.
Pipeline Overview
Oral Obesity Drugs in 2026 — Wegovy Pill vs Orforglipron vs VK2735→
Wegovy pill (first approved oral GLP-1), Eli Lilly’s orforglipron (Phase 3), and Viking’s oral VK2735 (Phase 2). Approval status, weight-loss data, and key differentiators.
Cluster 03
Approvals & Pipeline Tracker
Is it approved? What phase is it in? Status pages for every major obesity compound, plus a master tracker with month-by-month catalysts.
Status Page
Is Retatrutide Approved Yet? FDA Status & TRIUMPH Phase 3→
Not approved as of March 2026. Eli Lilly’s triple agonist is in Phase 3 TRIUMPH trials. Full regulatory status, trial readouts, and what to watch next.
Trial Tracker
Retatrutide TRIUMPH Trial Tracker — Phase 3 Results & Timeline→
Every TRIUMPH trial in one place: TRIUMPH-4 results (28.7% weight loss + knee OA pain relief), safety signals (12.2–18.2% discontinuation), readout dates, and NDA timeline.
Deep Dive
Retatrutide & Knee Osteoarthritis — TRIUMPH-4 Phase 3 Data→
TRIUMPH-4 reported 28.7% weight loss and clinically meaningful knee OA pain relief. Mechanical unloading, anti-inflammatory mechanisms, and comparison with tirzepatide SURMOUNT-OA.
Status Page
Is CagriSema Approved Yet? FDA Status & NDA Filing→
Novo Nordisk’s amylin+GLP-1 combination — NDA filing status, REDEFINE trial results, and expected FDA decision timeline.
Status Page
Is Orforglipron Approved Yet? FDA Status & Timeline→
Not approved as of March 2026. Eli Lilly’s oral GLP-1 reported positive Phase 3 ATTAIN-1 data — 12.4% weight loss at 72 weeks. Full status and what to watch next.
Status Page
Is Survodutide Approved Yet? FDA Status & SYNCHRONIZE Phase 3→
Boehringer Ingelheim’s dual GLP-1/glucagon agonist — Phase 3 SYNCHRONIZE programme status, expected milestones, and regulatory path.
Status Page
Is Oral VK2735 Approved Yet? Trial Status & Timeline→
Not approved as of March 2026. Viking Therapeutics’ Phase 2 VENTURE-Oral data showed up to 12.2% weight loss at 13 weeks. Phase 3 planned Q3 2026.
Master Tracker
Obesity Drug Approval Tracker 2026 — Every Major Pipeline Candidate→
Three FDA-approved, 7+ in Phase 3, 5+ in Phase 2. Retatrutide, orforglipron, CagriSema, survodutide, VK2735, petrelintide, and more — every major drug in one table.
Timeline
Obesity Drug Pipeline Timeline 2026 — Every Major Catalyst, Month by Month→
Month-by-month timeline of FDA decisions, Phase 3 readouts, NDA filings, and advisory committee meetings for the obesity drug pipeline.
Cluster 04
UAE Market & Availability
GLP-1 pricing in AED, obesity prevalence data, retatrutide availability in Dubai, and why the UAE is a key research market.
Market Analysis
Peptide Trends in UAE & Worldwide 2026 — Types, Rankings & Insights→
Global market at USD 49.68B, UAE fastest in MEA at 11.6% CAGR. GLP-1 agonists dominate. Top 5 popularity rankings, peptide types, oral delivery outlook, and AI-driven discovery trends.
UAE Market Guide
GLP-1 Medications in the UAE — Availability, Cost & Research Status→
Ozempic, Mounjaro, Wegovy pricing in AED, prescription requirements, insurance coverage gaps, and the investigational pipeline including retatrutide in the UAE market.
Market Data
Obesity in the UAE — 2026 Statistics & GLP-1 Landscape→
UAE obesity prevalence from the 440,000-person study, 19.3% diabetes rate, GLP-1 market projections (USD 371.6M by 2030), and why Dubai is a key research market.
UAE Availability
Retatrutide in Dubai — Triple Agonist Research Pen Availability→
Retatrutide research pen availability in the UAE — 30mg prefilled FlexiPen specs, Dubai delivery, COA verification, pricing in AED, and the triple agonist pathway.
Comparison / UAE
Ozempic Alternative Dubai — Why Researchers Are Looking Beyond Single-Agonist GLP-1→
Ozempic, Mounjaro, Wegovy, and retatrutide compared for Dubai researchers — AED pricing, receptor targets, clinical weight-loss data, rebound rates, and triple agonism.
UAE Market / Pricing
Mounjaro Dubai — Tirzepatide Price, Availability & Alternatives→
Mounjaro (tirzepatide) in Dubai: AED pricing by dose, pharmacy availability, insurance coverage gaps, prescription requirements, and how it compares to Ozempic and retatrutide in the UAE.
Cluster 05
Safety, Side Effects & Dosing
Adverse event data from clinical trials, dosing protocols, discontinuation outcomes, body composition effects, and non-diabetes indications.
Safety Data
Retatrutide Side Effects — Phase 2 Safety Data & Clinical Comparison→
Phase 2 adverse event data from Jastreboff et al. (NEJM 2023) — GI side effect rates, injection site reactions, cardiovascular data, and comparison with semaglutide and tirzepatide.
Dosage Reference
Retatrutide Dosage Guide — Titration Protocol & Click-to-Dose Reference→
TRIUMPH trial dosing protocol, week-by-week titration schedule from 0.5mg to 15mg, click-to-dose table for the 30mg pen, and research administration considerations.
Product Guide
Retatrutide Pen Guide — 30 mg FlexiPen Specifications & Usage→
Complete reference for the 30 mg retatrutide research pen: 300 clicks at 0.1 mg/click, dial mechanism, storage requirements, needle compatibility, and handling best practices.
Discontinuation Data
What Happens When You Stop GLP-1? Weight Regain Data→
STEP 1, STEP 4, and SURMOUNT-1 extension data on weight regain after GLP-1 discontinuation. Biology of weight regain and implications for multi-agonist research.
Body Composition
GLP-1 and Muscle Loss — What the Clinical Data Shows→
DEXA-measured lean mass data from semaglutide, tirzepatide, and retatrutide trials. How much muscle is lost, why it happens, and evidence-based preservation strategies.
Dermatology
Ozempic Face — Why GLP-1 Drugs Cause Facial Fat Loss→
GLP-1-induced facial aging explained: what causes it, which drugs carry the highest risk, clinical prevalence data, treatment options, and how retatrutide’s triple-agonist mechanism compares.
Drug Comparison
Saxenda vs Ozempic — Liraglutide vs Semaglutide Compared→
Head-to-head comparison of liraglutide (Saxenda) and semaglutide (Ozempic/Wegovy) — STEP 8 trial data, weight-loss efficacy, side effects, dosing, cardiovascular outcomes, and cost.
UAE Market
Wegovy Price & Dosing Guide UAE — Semaglutide 2.4 mg (2026)→
Wegovy in the UAE: monthly cost AED 1,200–1,500, full 5-step titration schedule, STEP 1 trial data (14.9% weight loss), pen specifications, pharmacy availability, and how retatrutide compares.
Drug Comparison
Weight Loss Injections Compared — Wegovy vs Mounjaro vs Saxenda vs Zepbound→
Every major injectable obesity treatment compared: semaglutide, tirzepatide, liraglutide, and retatrutide. Clinical trial weight loss data, dosing schedules, side effect profiles, and UAE availability.
Drug Profile
Mounjaro (Tirzepatide) Injection Guide — Dosing, Weight Loss & Side Effects→
Complete tirzepatide guide: dual GLP-1/GIP mechanism, SURMOUNT trial data (22.4% weight loss), 6-step dosing schedule, side effects, body composition, UAE availability, and comparison with retatrutide.
Drug Profile
Rybelsus (Oral Semaglutide) — Tablets, Dosing, Weight Loss & Side Effects→
The first oral GLP-1 tablet: SNAC absorption technology, PIONEER and OASIS trial data, 3/7/14 mg dosing protocol, strict administration requirements, UAE availability, and how Rybelsus compares to Ozempic and Mounjaro.
Clinical Outcomes
Ozempic & Mounjaro Before and After — Real Weight Loss Results→
Clinical trial weight loss timelines, body composition data, responder vs non-responder analysis, Ozempic face, discontinuation and weight regain, and how results compare to retatrutide and CagriSema.
Clinical Review
Which Obesity Drugs Actually Matter for Sleep Apnea?→
Zepbound, retatrutide, and the OSA pipeline. Which compounds have sleep apnea data, which are FDA-approved for the indication, and what the evidence actually shows.
Research Overview
GLP-1 for Non-Diabetics — What the Research Shows→
Approved and investigational non-diabetes indications — obesity, cardiovascular risk (SELECT trial), MASH, heart failure, kidney disease, sleep apnea, and more.
Cluster 06
Guides & Resources
Practical reference material — storage protocols, sourcing guides, and deep dives on specific research topics.
Storage Guide
Peptide Stability & Storage Guide→
Lyophilized vs. reconstituted shelf life data for 8 research compounds. Storage temperatures, recommended solvents, reconstitution best practices, and prefilled pen vs. vial comparison.
B2B Sourcing
Peptide Raw Powder Sourcing — What Distributors Need to Know in 2026→
Supplier due diligence, HPLC CoA interpretation, third-party testing, regulatory frameworks (EU, US, Brazil, UAE), cold-chain logistics, and wholesale pricing structures.
Sourcing Guide
Where to Buy Retatrutide — Sourcing Research-Grade Peptide→
How to source research-grade retatrutide: supplier verification, HPLC purity standards, COA interpretation, red flags, regulatory status, and what to look for in a legitimate peptide vendor.
Peptide Research
Looksmaxxing and Peptides — The Science Behind the Trend→
Clinical data on GHK-Cu, BPC-157, MK-677, GLP-1 body composition, collagen synthesis pathways, and growth hormone secretagogues. Evidence-based breakdown of trending compounds.
ORDER
Retatrutide Pen 30 mg
99.262% HPLC purity, Janoshik Analytical. 300 clicks per pen, ships from Dubai.
Order Retatrutide Pen →